News and events
When results are so encouraging, the path is traced: one step at a time towards the cure ~ Hemera’s Team
REMaST® and the Immunity publication: Hemera’s therapy in the spotlight of national media
From TG3 Leonardo to national media: press recognition supports Hemera’s path toward the clinical phase Following the recent publication in the...
Hemera announces the publication in Immunity of preclinical discoveries on REMaST® for neural tissue regeneration
A peer-reviewed study demonstrates the therapeutic potential of REMaST® in spinal cord repair and neuronal regeneration Hemera is pleased to...
Published in STAR Protocols: Severe contusive preclinical model confirms the preclinical value of REMaST®
Researchers at Hemera, including co-founders Ilaria Decimo and Francesco Bifari and senior scientist Sissi Dolci, have published a key study in STAR...
Cristiana Vignoli and Hemera’s Entrepreneurial Vision Featured in Il Sole 24 Ore
Il Sole 24 Ore insert dedicated to the BFactor Award by the Fondazione Marisa Bellisario was released, featuring a profile of the winners. Among...
Michela Pantaleoni joins Hemera’s Board of Directors
Hemera is pleased to announce the appointment of Michela Pantaleoni to its Board of Directors. Michela brings over twenty years of experience in the...
Hemera on TV: Cristiana Vignoli’s interview on TG2 on RAI 2
CEO Hemera interviews on national italian TV TG2
Cristiana Vignoli Appointed Sole Director of Proemera
Cristiana Vignoli, CEO of Hemera, has been appointed Sole Director of Proemera, the main investment vehicle supporting Hemera since its foundation....
Our CEO Cristiana Vignoli wins the Bellisario BFactor 2025 Award
Cristiana Vignoli, CEO of Hemera, has been awarded the BFactor 2025 Prize as part of the fifth edition of the initiative promoted by the Marisa...
Hemera presents advances in REMaST research at the Science, Technology and Business Days 2025 in Boston
During the Life Sciences session on the third day of the STB Days 2025, an event organized by the General Consulate of Italy in Boston to highlight...
Hemera receives the Seal of Excellence from the European Commission for the REMaST project
Hemera recently participated in the prestigious European program EIC Accelerator, promoted by the European Commission to support high-impact...
European Patent Granted for REMaST: a Key Step in Enhancing Hemera’s Intellectual Property
The European patent for REMaST, Hemera’s proprietary technology for nervous tissue regeneration, has been published in Issue 24/25 of the European Patent Office (EPO) Bulletin on June 11, 2025…
We warmly welcome Statuto Fiduciaria among Hemera’s supporters
We are pleased to announce the entry of Statuto Fiduciaria as a new shareholder, representing the subscribers of the SAFE
Hemera goes to Brussels for the Final Phase of the EIC Accelerator
Hemera is among the 7 Italian startups out of 71 selected across Europe, that successfully passed the second phase of the EIC Accelerator selection process
Hemera at the Chamber of Deputies to Receive the 2025 America Innovation Award
Hemera has been selected among 300 Italian entrepreneurial ventures as a recipient of the America Innovation Award, promoted by the Italy–USA Foundation and presented at the Chamber of Deputies in Rome
Research by Hemera Scientists on Nature Immunology Review
The study titled “Tumor-associated macrophages enhance tumor innervation and spinal cord repair”, to which our researchers contributed, was recently published by Nature Reviews Immunology
Interview with Hemera on Byoblu: Focus on Cell Therapies for Nerve Regeneration
Byoblu interviews Professors Bifari and Locati, co-founders of Hemera, to explore the scientific foundations of our REMaST cell therapy
Hemera Receives a “GO” in Phase 1 of the EIC Accelerator
We are pleased to announce that our proposal successfully passed the short application stage, receiving the first “GO” in the evaluation process.
Cytotherapy Mentions Hemera as One of the Most Promising Players in Cell Therapy
Hemera was recently featured in Cytotherapy, the official journal of the International Society for Cell & Gene Therapy,
Preprint Published: Hemera’s REMaST Research Marks a Breakthrough in Nerve Regeneration
We are pleased to announce the preprint publication of the scientific article presenting the results of our groundbreaking research on the REMaST therapy
Hemera Among the Top 8 Health Startups
We are proud to announce that Hemera has been included in the list of the 8 emerging startups revolutionizing the healthcare sector, as reported by Milano Finanza.
Hemera Wins the 2024 Italian Master Startup Award in the Life Sciences MED-Tech Category
Hemera has been named co-winner of the 2024 IMSA – Italian Master Startup Award in the Life Sciences MED-Tech category, alongside ALBA Robot.
Hemera Named Finalist at the 2024 Italian Master Startup Award
We are pleased to announce that Hemera Pharma has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research.
Hemera Presents the Progress of REMaST®️ Therapy at the FENS Forum 2024
Hemera Pharma is participating in the FENS Forum 2024, the leading European congress on neuroscience, held from June 25 to 29 in Vienna. The teams from the Therapy Development Department and the Research and Development Department, led by Prof. Ilaria Decimo, will present the development of the REMaST®️ therapy (Regenerative Educated Macrophages Self Transplantation).
We are pleased to welcome Humanitas Mirasole S.p.A. among Hemera’s shareholders
We are pleased to announce that Istituto Clinico Humanitas Mirasole S.p.A. has joined Hemera’s shareholding structure
Hemera at ISCT 2024: Innovation and Cutting-Edge Cell Therapies
Hemera enthusiastically participated in ISCT 2024, the event organized by the International Society for Cell & Gene Therapy, held in Vancouver...
Innovation Coffee: Advancements in REMaST® Therapy and the Mission to Regenerate Nervous Tissue.
In the context of the "Healing the Incurable" Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the...
Scientific Venture Capital Selects Hemera Among Italy’s Most Innovative Deep-Tech Companies
Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative...
Scientifica Venture Capital selects Hemera among the most innovative deep-tech companies in Italy
Important Recognition for REMaST® Therapy: A New Perspective for Patients with Spinal Cord Injuries Hemera has been selected among the most...
A study has been initiated to observe patients with traumatic and complete spinal cord injury.
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective...
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy
The prospective observational clinical study is now underway, involving patients with acute, complete traumatic spinal cord injury, who will be monitored over a 12-month period during their neurorehabilitation journey.
Stay informed on Hemera’s latest activities with our Newsletter.